

July 23, 2019

Siri & Glimstad LLP 200 Park Avenue Seventeenth Floor New York, NY 10166

In reply, refer to file: F18-6943

Dear Mr. Siri,

This is in reply to your Freedom of Information Act request dated August 22, 2018, in which you requested "A copy of the report for each clinical trial relied upon by the FDA when approving Ipol in 1990." Your request was received in the Center for Biologics Evaluation and Research on August 24, 2018.

A search of the IPOL product license application file located the enclosed documents that are responsive to your request. Please note that we have provided you with the best available copies of the records.

We have withheld portions of pages under Exemption (b)(4), 5 U.S.C. § 522(b)(4). That exemption permits the withholding of trade secrets and commercial or financial information that was obtained from a person outside the government and that is privileged or confidential. The withholding of such information is permitted if disclosure is likely to cause substantial competitive harm to the person who submitted the information.

In addition, we have withheld portions of pages under Exemption (b)(6), 5 U.S.C. § 522(b)(6). That exemption protects information from disclosure when its release would cause a clearly unwarranted invasion of personal privacy. FOIA Exemption 6 is available to protect information in personnel or medical files and similar files. This requires a balancing of the public's right to disclosure against the individual's right to privacy.

You have the right to appeal this determination. By filing an appeal, you preserve your rights under FOIA and give the agency a chance to review and reconsider your request and the agency's decision.

Your appeal must be mailed within 90 days from the date of this response to:

Deputy Agency Chief FOIA Officer
U.S. Department of Health and Human Services
Office of the Assistant Secretary for Public Affairs
Room 729H
200 Independence Avenue, S.W.
Washington, DC 20201
Email: FOIARequest@PSC.hhs.gov

Please clearly mark both the envelope and your letter or email "**FDA** Freedom of Information Act Appeal."

If you would like to discuss our response <u>before</u> filing an appeal to attempt to resolve your dispute without going through the appeals process, please contact:

Beth Brockner-Ryan, Branch Chief
Center for Biologics Evaluation and Research (CBER)
Access Litigation and Freedom of Information Branch
U.S. Food and Drug Administration
10903 New Hampshire Avenue
Building 71, Room 1114
Silver Spring, MD 20993-0002
Email: beth.brocknerryan@fda.hhs.gov
Main Line 240-402-7800
FOI Line 240-402-8008

You also have the right to contact:

FDA FOIA Public Liaison Office of the Executive Secretariat 5630 Fishers Lane Room-1050 Rockville, MD 20857

Email: FDAFOIA@fda.hhs.gov

If you are unable to resolve your FOIA dispute through our FOIA Public Liaison, the Office of Government Information Services (OGIS), the Federal FOIA Ombudsman's office, offers mediation services to help resolve disputes between FOIA requesters and Federal agencies. The contact information for OGIS is:

Office of Government Information Services National Archives and Records Administration 8601 Adelphi Road–OGIS College Park, MD 20740-6001 Telephone: 202-741-5770

Toll-Free: 1-877-684-6448 E-mail: ogis@nara.gov Fax: 202-741-5769

The following may be included in a monthly invoice:

The above charges may not reflect final charges for this request. Please DO NOT send any payment until you receive an invoice from the Agency's Freedom of Information Staff (HFI-35).

referencing the above file number. You can contact Mechelle Bray by phone at 240-402-8024 or by e-mail at Mechelle.Bray@fda.hhs.gov.	
	Sincerely,
	Beth Brockner Ryan Chief, Access Litigation and Freedom of Information Branch